- Report
- December 2025
- 150 Pages
Global
From €5295EUR$5,950USD£4,598GBP
- Report
- August 2025
- 100 Pages
Global
From €5295EUR$5,950USD£4,598GBP
- Report
- May 2025
- 120 Pages
Global
From €5295EUR$5,950USD£4,598GBP
- Report
- May 2025
- 200 Pages
Global
From €2216EUR$2,490USD£1,924GBP
- Report
- January 2026
- 198 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 180 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 193 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 180 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 181 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 197 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 196 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 185 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 180 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 190 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 185 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 190 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 182 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 197 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 197 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 184 Pages
Global
From €3505EUR$3,939USD£3,044GBP

The Dry Powder Inhaler (DPI) market is a segment of the respiratory drugs market. It is a device used to deliver medication to the lungs in the form of a dry powder. It is a convenient and efficient way to deliver medication to the lungs, as it does not require the use of a propellant gas. DPIs are used to treat a variety of respiratory conditions, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. They are also used to deliver vaccines and other medications.
DPIs are becoming increasingly popular due to their convenience and effectiveness. They are also cost-effective, as they require fewer components than other inhalers. Additionally, DPIs are easy to use and can be used by patients of all ages.
Several companies are involved in the DPI market, including GlaxoSmithKline, Boehringer Ingelheim, Novartis, Merck, and AstraZeneca. These companies are involved in the development, manufacture, and marketing of DPIs. Show Less Read more